Whitehawk Therapeutics Spotlights ADC Pipeline, Cash Runway Through 2028

CEO Dave Lennon outlines company's next-generation ADC strategy at healthcare conference

Published on Feb. 25, 2026

Got story updates? Submit your updates here. ›

Whitehawk Therapeutics CEO Dave Lennon highlighted the company's antibody-drug conjugate (ADC) pipeline and development approach during a presentation at an annual healthcare conference. Lennon discussed Whitehawk's focus on engineering 'better ADCs' through improvements in targeting, bioconjugation, and linker/payload design. He outlined the company's three clinical-stage ADC programs, including HWK-007 targeting PTK7, HWK-016 targeting MUC16 for gynecological cancers, and HWK-206 targeting SEZ6, which is expected to enter the clinic in Q3 2026.

Why it matters

Whitehawk's approach to ADC development aims to address limitations of first-generation ADCs, such as instability, off-target toxicity, and suboptimal tumor targeting. The company's pipeline represents an effort to engineer more potent and better-tolerated ADCs that could improve outcomes for cancer patients. As the ADC field continues to evolve, Whitehawk's progress will be closely watched.

The details

Whitehawk launched in 2025 after in-licensing a three-asset ADC portfolio from WuXi Biologics. The company had $160 million in cash as of Q3 2025, providing a runway into 2028. Lennon highlighted Whitehawk's use of high-affinity antibodies, an attenuated Fc portion to limit toxicity, a 'paired carbon-bonded linker payload' for stability, and a proprietary Topo-1 inhibitor payload. In preclinical studies, Whitehawk's ADCs demonstrated 3-10x greater tumor potency, 5-25x improved stability, and a 2-3x higher safety margin versus average Topo-1 inhibitor ADCs.

  • Whitehawk launched in early 2025 after in-licensing the ADC portfolio.
  • The company had $160 million in cash as of the end of Q3 2025, providing a runway into 2028.
  • Whitehawk plans to release additional preclinical data packages supporting its three programs in spring 2026.
  • The company is currently enrolling patients in phase I dose-escalation studies for HWK-007 and HWK-016, with clinical readouts expected in the first half of 2027.
  • Whitehawk expects to file an IND and start a phase I trial for HWK-206 in Q3 2026.

The players

Whitehawk Therapeutics

An American biopharmaceutical company focused on developing next-generation antibody-drug conjugates (ADCs).

Dave Lennon

The CEO of Whitehawk Therapeutics who outlined the company's ADC strategy and pipeline during a healthcare conference presentation.

Pfizer

A pharmaceutical company that previously developed a first-generation PTK7-directed ADC called cofetuzumab pelidotin.

AbbVie

A biopharmaceutical company that is developing a SEZ6-directed ADC called ABBV-706, which Whitehawk's HWK-206 program is designed to compete with.

WuXi Biologics

A Chinese contract research and manufacturing organization from which Whitehawk in-licensed its initial ADC portfolio.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.